EUVIMEDEUVIMED entdecken
Crossref

The immune-reinforcements of Lenvatinib plus anti-PD-1 and their rationale to unite with TACE for unresectable hepatocellular carcinoma treatment

Jiayun Jiang, Hui Zhang, Yanjiao Ou, Jiejuan Lai, Yulan Huang, Wenyun Cai, Chong Li, Leida Zhang, Yu Fu

Immunology Letters · 2025-10 · 275 · 107003

DOI: 10.1016/j.imlet.2025.107003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Immunology Letters, 2025-10. Verfasst von Jiayun Jiang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Hepatobiliary Surgery, Southwest Hospital, Third Military Medical University/Army Medical University, Chongqing, 400038, PR China. Hauptthemen laut MEDLINE: Phenylurea Compounds, Carcinoma, Hepatocellular, Quinolines, Chemoembolization, Therapeutic. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: Natural Science Foundation of Chongqing Municipality, Third Military Medical University Southwest Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Despite encouraging clinical benefits have gained by anti-PD-1 and Lenvatinib combination, in-depth characterizations about the mechanisms of action remain poorly characterized. Furthermore, although the combination of systemic anti-PD-1 or Lenvatinib treatment and locoregional transcatheter arterial chemoembolization (TACE) is widely carried out to treat unresectable HCC in clinical, the efficacies of different combination regimens are uncertain due to limited researches. METHODS: We firstly generated murine HCC models to validate the enhanced anti-tumor effects of anti-PD-1 and Lenvatinib combination therapy. Then single cell mass cytometry (CyTOF) was employed to phenotypically reveal their mechanisms of action. After that, we further compared the effectiveness of TACE plus Lenvatinib (i.e., TACE-Len) dual therapy with TACE, Lenvatinib plus anti-PD-1 (i.e., TACE-Len-PD-1) triple therapy as conversion therapy for unresectable HCC. RESULTS: Lenvatinib and anti-PD-1 combination could generate activated immune profiles not only by increasing systemic CD4+, CD8+T cells and B cells proportions, but also by weakening the immune-tolerance functions derived from both immunosuppressive cells (i.e., MDSCs) and co-inhibitory mediators (i.e., PD-L1 and LAG-3). Meanwhile, our study also suggested that TACE-Len-PD-1 triple therapy could achieve better clinical responses with powerful immune profiles for unresectable HCC compared to TACE-Len dual therapy. CONCLUSIONS: Our study provided a delicate immune landscape of anti-PD-1and Lenvatinib combination, and we also offered scientific evidences that TACE-Len-PD-1 triple therapy could fulfill better clinical benefits than TACE-Len dual therapy, which is anticipated to provide objective and effective evidences for clinical use.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Phenylurea CompoundsCarcinoma, HepatocellularQuinolinesChemoembolization, TherapeuticLiver NeoplasmsProgrammed Cell Death 1 ReceptorImmune Checkpoint InhibitorsAntineoplastic Combined Chemotherapy ProtocolsAnimalsMiceHumansDisease Models, AnimalCell Line, TumorCombined Modality TherapyMale

Stichwörter der Autor:innen

Anti-PD-1CyTOFHepatocellular carcinomaLenvatinibTACE

Substanzen

lenvatinibPhenylurea CompoundsQuinolinesProgrammed Cell Death 1 ReceptorImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Institute of Hepatobiliary Surgery, Southwest Hospital, Third Military Medical University/Army Medical University, Chongqing, 400038, PR China.
  • Medical Research Institute, College of Pharmaceutical Sciences, Southwest University, Chongqing, 400715, PR China.
  • Medical Research Institute, College of Pharmaceutical Sciences, Southwest University, Chongqing, 400715, PR China. Electronic address: chongli@swu.edu.cn.
  • Institute of Hepatobiliary Surgery, Southwest Hospital, Third Military Medical University/Army Medical University, Chongqing, 400038, PR China. Electronic address: 2518569931@qq.com.
  • Medical Research Institute, College of Pharmaceutical Sciences, Southwest University, Chongqing, 400715, PR China. Electronic address: fuyu2020@swu.edu.cn.

Förderung

  • Natural Science Foundation of Chongqing Municipality
  • Third Military Medical University Southwest Hospital

Zitieren

APA

Jiang, J., Zhang, H., Ou, Y., Lai, J., Huang, Y., Cai, W., Li, C., Zhang, L., & Fu, Y. (2025). The immune-reinforcements of Lenvatinib plus anti-PD-1 and their rationale to unite with TACE for unresectable hepatocellular carcinoma treatment. Immunology Letters, 275, 107003. https://doi.org/10.1016/j.imlet.2025.107003

Vancouver

Jiang J, Zhang H, Ou Y, Lai J, Huang Y, Cai W, et al. The immune-reinforcements of Lenvatinib plus anti-PD-1 and their rationale to unite with TACE for unresectable hepatocellular carcinoma treatment. Immunology Letters. 2025;275:107003. doi:10.1016/j.imlet.2025.107003

BibTeX
@article{Jiang2025,
  author = {Jiang, Jiayun and Zhang, Hui and Ou, Yanjiao and Lai, Jiejuan and Huang, Yulan and Cai, Wenyun and Li, Chong and Zhang, Leida and Fu, Yu},
  title = {The immune-reinforcements of Lenvatinib plus anti-PD-1 and their rationale to unite with TACE for unresectable hepatocellular carcinoma treatment},
  journal = {Immunology Letters},
  year = {2025},
  volume = {275},
  pages = {107003},
  doi = {10.1016/j.imlet.2025.107003}
}
Kostenlos starten →